c

cbdMD Inc
AMEX:YCBD

Watchlist Manager
cbdMD Inc
AMEX:YCBD
Watchlist
Price: 0.82045 USD -1.81% Market Closed
Market Cap: $7.3m

Relative Value

The Relative Value of one YCBD stock under the Base Case scenario is 1.75821 USD. Compared to the current market price of 0.82045 USD, cbdMD Inc is Undervalued by 53%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

YCBD Relative Value
Base Case
1.75821 USD
Undervaluation 53%
Relative Value
Price
c
Worst Case
Base Case
Best Case

Multiples Across Competitors

YCBD Competitors Multiples
cbdMD Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
cbdMD Inc
AMEX:YCBD
7.1m USD 0.4 -1.6 -4.9 -2.3
US
Eli Lilly and Co
NYSE:LLY
1T USD 17 54.8 36.8 39.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
528.7B USD 5.6 19.7 13.8 16.9
CH
Roche Holding AG
SIX:ROG
275.3B CHF 4.5 29.2 12.4 14.5
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP 4.9 30.2 19.7 28.8
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 5.6 17.2 11.9 13.9
CH
Novartis AG
SIX:NOVN
221.9B CHF 5 19.5 15.7 20.2
US
Merck & Co Inc
NYSE:MRK
267.9B USD 4.2 14.1 10 11.8
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
145.6B USD 2.3 14.8 7.5 10.3
P/E Multiple
Earnings Growth PEG
US
c
cbdMD Inc
AMEX:YCBD
Average P/E: 24.9
Negative Multiple: -1.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.8
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.7
6%
3.3
CH
Roche Holding AG
SIX:ROG
29.2
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.2
38%
0.8
DK
Novo Nordisk A/S
CSE:NOVO B
17.2
2%
8.6
CH
Novartis AG
SIX:NOVN
19.5
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.1
14%
1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
c
cbdMD Inc
AMEX:YCBD
Average EV/EBITDA: 431.9
Negative Multiple: -4.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.8
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.8
2%
6.9
CH
Roche Holding AG
SIX:ROG
12.4
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
19.7
10%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.9
1%
11.9
CH
Novartis AG
SIX:NOVN
15.7
6%
2.6
US
Merck & Co Inc
NYSE:MRK
10
6%
1.7
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
c
cbdMD Inc
AMEX:YCBD
Average EV/EBIT: 1 872.3
Negative Multiple: -2.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.4
37%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.9
6%
2.8
CH
Roche Holding AG
SIX:ROG
14.5
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
28.8
23%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.9
0%
N/A
CH
Novartis AG
SIX:NOVN
20.2
12%
1.7
US
Merck & Co Inc
NYSE:MRK
11.8
8%
1.5
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5